Brian Hunter

1.0k total citations
18 papers, 843 citations indexed

About

Brian Hunter is a scholar working on Pharmacology, Experimental and Cognitive Psychology and Molecular Biology. According to data from OpenAlex, Brian Hunter has authored 18 papers receiving a total of 843 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Pharmacology, 3 papers in Experimental and Cognitive Psychology and 2 papers in Molecular Biology. Recurrent topics in Brian Hunter's work include Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (3 papers), Treatment of Major Depression (3 papers) and Perfectionism, Procrastination, Anxiety Studies (2 papers). Brian Hunter is often cited by papers focused on Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (3 papers), Treatment of Major Depression (3 papers) and Perfectionism, Procrastination, Anxiety Studies (2 papers). Brian Hunter collaborates with scholars based in United States, Switzerland and United Kingdom. Brian Hunter's co-authors include Cornelius Katona, B. J. Marsh, Susan L. Stevens, Mary P. Stenzel‐Poore, Amy E.B. Packard, Christina A. Harrington, Philberta Y. Leung, Banu Gopalan, Luigi Giorgi and Dan J. Stein and has published in prestigious journals such as Journal of Neuroscience, Molecular and Cellular Biology and Neurology.

In The Last Decade

Brian Hunter

18 papers receiving 816 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Brian Hunter United States 11 251 169 141 137 133 18 843
Laura Grosse Germany 16 184 0.7× 114 0.7× 152 1.1× 67 0.5× 70 0.5× 21 834
Cem İ̇smail Küçükali Türkiye 21 339 1.4× 127 0.8× 202 1.4× 32 0.2× 82 0.6× 82 1.0k
Jean Marie Launay France 17 313 1.2× 75 0.4× 183 1.3× 83 0.6× 88 0.7× 37 963
Jesús Lovera United States 20 241 1.0× 96 0.6× 168 1.2× 44 0.3× 115 0.9× 33 1.2k
Cheri Lubahn United States 15 176 0.7× 191 1.1× 112 0.8× 52 0.4× 76 0.6× 24 742
M. Féchir Germany 16 244 1.0× 54 0.3× 61 0.4× 177 1.3× 70 0.5× 19 804
Hua Zheng China 17 204 0.8× 61 0.4× 54 0.4× 69 0.5× 52 0.4× 48 858
Erin L. Scott United States 12 235 0.9× 136 0.8× 28 0.2× 21 0.2× 57 0.4× 16 653
Yoshio Kaneko Japan 15 233 0.9× 60 0.4× 139 1.0× 43 0.3× 19 0.1× 19 880
Harm de Wit Netherlands 14 183 0.7× 86 0.5× 226 1.6× 30 0.2× 109 0.8× 17 867

Countries citing papers authored by Brian Hunter

Since Specialization
Citations

This map shows the geographic impact of Brian Hunter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian Hunter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian Hunter more than expected).

Fields of papers citing papers by Brian Hunter

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian Hunter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian Hunter. The network helps show where Brian Hunter may publish in the future.

Co-authorship network of co-authors of Brian Hunter

This figure shows the co-authorship network connecting the top 25 collaborators of Brian Hunter. A scholar is included among the top collaborators of Brian Hunter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian Hunter. Brian Hunter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Wiendl, Heinz, Laura Airas, Tanuja Chitnis, et al.. (2023). Phase 3 REMODEL I/II Trials: Efficacy, Safety, and Tolerability of Remibrutinib in Patients with Relapsing Multiple Sclerosis. Multiple Sclerosis and Related Disorders. 80. 105315–105315. 1 indexed citations
2.
Wiendl, Heinz, Laura Airas, Tanuja Chitnis, et al.. (2022). Phase 3 REMODEL I/II Trials: Effectiveness, Safety, and Tolerability of Remibrutinib in Patients with Relapsing Multiple Sclerosis (P7-4.003). Neurology. 98(18_supplement). 1 indexed citations
3.
Hunter, Brian, et al.. (2019). A Comparison of Venous versus Capillary Blood Samples when Measuring Blood Glucose Using a Point-of-Care, Capillary-Based Glucometer. Prehospital and Disaster Medicine. 34(5). 506–509. 16 indexed citations
4.
5.
Kappos, Ludwig, David K.B. Li, Olaf Stüve, et al.. (2016). Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis. JAMA Neurology. 73(9). 1089–1089. 82 indexed citations
6.
Kappos, Ludwig, Olaf Stüve, Hans Hartung, et al.. (2014). Safety and Efficacy of Siponimod (BAF312) in Patients with Relapsing-remitting Multiple Sclerosis: Results from Dose-blinded Extension Phase of BOLD Study (P3.151). Neurology. 82(10_supplement). 1 indexed citations
7.
8.
Stocchi, Fabrizio, Luigi Giorgi, Brian Hunter, & Anthony H.V. Schapira. (2011). PREPARED: Comparison of prolonged and immediate release ropinirole in advanced Parkinson's disease. Movement Disorders. 26(7). 1259–1265. 64 indexed citations
9.
Marsh, B. J., Susan L. Stevens, Amy E.B. Packard, et al.. (2009). Systemic Lipopolysaccharide Protects the Brain from Ischemic Injury by Reprogramming the Response of the Brain to Stroke: A Critical Role for IRF3. Journal of Neuroscience. 29(31). 9839–9849. 189 indexed citations
10.
Marsh, B. J., Susan L. Stevens, Brian Hunter, & Mary P. Stenzel‐Poore. (2008). Inflammation and the Emerging Role of the Toll-Like Receptor System in Acute Brain Ischemia. Stroke. 40(3_suppl_1). S34–7. 41 indexed citations
11.
Wang, Zhiping, Tara J. Dillon, Snigdha Mishra, et al.. (2006). Rap1-Mediated Activation of Extracellular Signal-Regulated Kinases by Cyclic AMP Is Dependent on the Mode of Rap1 Activation. Molecular and Cellular Biology. 26(6). 2130–2145. 138 indexed citations
12.
Yonkers, Kimberly A., et al.. (2003). Paroxetine Controlled Release Is Effective in Treating Premenstrual Dysphoric Disorder. Obstetrics and Gynecology. 101(Supplement). 110S–111S. 2 indexed citations
13.
Stein, Dan J., et al.. (2002). Predictors of Response to Pharmacotherapy in Social Anxiety Disorder. The Journal of Clinical Psychiatry. 63(2). 152–155. 72 indexed citations
14.
Stein, Dan J., et al.. (2001). The selective serotonin reuptake inhibitor paroxetine is effective in more generalized and in less generalized social anxiety disorder. Psychopharmacology. 158(3). 267–272. 31 indexed citations
15.
Katona, Cornelius, et al.. (1998). A double-blind comparison of the efficacy and safety of paroxetine and imipramine in the treatment of depression with dementia. International Journal of Geriatric Psychiatry. 13(2). 100–108. 119 indexed citations
16.
Katona, Cornelius, et al.. (1998). A double‐blind comparison of the efficacy and safety of paroxetine and imipramine in the treatment of depression with dementia. International Journal of Geriatric Psychiatry. 13(2). 100–108. 5 indexed citations
17.
Hunter, Brian, et al.. (1998). Correlation of body mass index with thoracic and abdominal panniculus.. PubMed. 43(2). 427–30. 3 indexed citations
18.
Judge, Rajinder, et al.. (1997). A Double-Blind, Multicenter Study in Primary Care Comparing Paroxetine and Clomipramine in Patients With Depression and Associated Anxiety. The Journal of Clinical Psychiatry. 58(3). 112–118. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Laura Grosse Breakdown of academic impact, for papers by Cem İ̇smail Küçükali Breakdown of academic impact, for papers by Jean Marie Launay Breakdown of academic impact, for papers by Jesús Lovera Breakdown of academic impact, for papers by Cheri Lubahn Breakdown of academic impact, for papers by M. Féchir Breakdown of academic impact, for papers by Hua Zheng Breakdown of academic impact, for papers by Erin L. Scott Breakdown of academic impact, for papers by Yoshio Kaneko Breakdown of academic impact, for papers by Harm de Wit
Rankless by CCL
2026